164 related articles for article (PubMed ID: 28962537)
1. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin Population Pharmacokinetics in the First Year of Life.
Moffett BS; Galati M; Mahoney D; Lee-Kim Y; Teruya J; Shah MD; Yee DL
Ther Drug Monit; 2017 Dec; 39(6):632-639. PubMed ID: 28937536
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
Brown A; Faraklas I; Ghanem M; Cochran A
J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
[TBL] [Abstract][Full Text] [Related]
4. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Enoxaparin After Renal Transplantation in Pediatric Patients.
Damamme A; Urien S; Borgel D; Lasne D; Krug P; Krid S; Charbit M; Salomon R; Treluyer JM; Boyer O
J Clin Pharmacol; 2018 Dec; 58(12):1597-1603. PubMed ID: 30256422
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
8. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin and antifactor Xa levels in acute burn patients.
Lin H; Faraklas I; Cochran A; Saffle J
J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231
[TBL] [Abstract][Full Text] [Related]
10. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
[TBL] [Abstract][Full Text] [Related]
12. Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
Yost RJ; Haan BJ; Mangan KC
Pharmacotherapy; 2018 Nov; 38(11):e82-e86. PubMed ID: 30129107
[TBL] [Abstract][Full Text] [Related]
13. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
Hulot JS; Vantelon C; Urien S; Bouzamondo A; Mahé I; Ankri A; Montalescot G; Lechat P
Ther Drug Monit; 2004 Jun; 26(3):305-10. PubMed ID: 15167633
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
16. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
17. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics Associated With Higher Enoxaparin Dosing Requirements for Venous Thromboembolism Prophylaxis in Trauma Patients.
Hashim YM; Dhillon NK; Veatch JM; Barmparas G; Ley EJ
Am Surg; 2021 Jul; 87(7):1177-1181. PubMed ID: 33342267
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
